Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients Read more about Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results Read more about Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain Disorders Read more about Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain Disorders Larimar Therapeutics Announces Oral Presentation at the Upcoming Gordon Research Conference on Mitochondria and Chloroplasts Read more about Larimar Therapeutics Announces Oral Presentation at the Upcoming Gordon Research Conference on Mitochondria and Chloroplasts Larimar Therapeutics Announces Upcoming Scientific Conference Presentations Read more about Larimar Therapeutics Announces Upcoming Scientific Conference Presentations Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress Read more about Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results Read more about Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results Read more about Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results Larimar Therapeutics Provides Update on CTI-1601 Clinical Program Read more about Larimar Therapeutics Provides Update on CTI-1601 Clinical Program Larimar Therapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference Read more about Larimar Therapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last » Subscribe to
Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients Read more about Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients
Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results Read more about Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results
Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain Disorders Read more about Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain Disorders
Larimar Therapeutics Announces Oral Presentation at the Upcoming Gordon Research Conference on Mitochondria and Chloroplasts Read more about Larimar Therapeutics Announces Oral Presentation at the Upcoming Gordon Research Conference on Mitochondria and Chloroplasts
Larimar Therapeutics Announces Upcoming Scientific Conference Presentations Read more about Larimar Therapeutics Announces Upcoming Scientific Conference Presentations
Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress Read more about Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress
Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results Read more about Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results
Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results Read more about Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results
Larimar Therapeutics Provides Update on CTI-1601 Clinical Program Read more about Larimar Therapeutics Provides Update on CTI-1601 Clinical Program
Larimar Therapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference Read more about Larimar Therapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference